ImmunityBio (IBRX) Receivables - Net (2014 - 2026)

ImmunityBio (IBRX) has reported Receivables - Net for 8 consecutive years, with $43.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 154.1% year-over-year to $43.3 million; the TTM figure through Mar 2026 stood at $43.3 million (up 154.1% YoY), while the FY2025 annual figure was $42.6 million, up 1703.86% from the prior year.
• Receivables - Net improved to $43.3 million in Q1 2026 per IBRX's latest filing, from $42.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $43.3 million in Q1 2026 and bottomed at $600000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $14.1 million across 5 years, with a median of $3.3 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Net jumped 72.17% — and 2025, when it surged 2041.92%.
• ImmunityBio's Receivables - Net stood at $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then surged by 81.54% to $2.4 million in 2024, then soared by 1703.86% to $42.6 million in 2025, then grew by 1.64% to $43.3 million in 2026.
• Business Quant data shows IBRX's Receivables - Net at $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $32.0 million in Q3 2025.